company background image
ALLK logo

Allakos NasdaqGS:ALLK Stock Report

Last Price

US$1.19

Market Cap

US$116.1m

7D

-7.8%

1Y

-56.4%

Updated

30 Dec, 2024

Data

Company Financials +

Allakos Inc.

NasdaqGS:ALLK Stock Report

Market Cap: US$116.1m

ALLK Stock Overview

A clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. More details

ALLK fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the US market

Shareholders have been diluted in the past year

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Allakos Inc. Competitors

Protara Therapeutics

NasdaqGM:TARA

US$113.7m

Acumen Pharmaceuticals

NasdaqGS:ABOS

US$106.9m

Lineage Cell Therapeutics

NYSEAM:LCTX

US$109.5m

Leap Therapeutics

NasdaqCM:LPTX

US$113.0m

Price History & Performance

Summary of share price highs, lows and changes for Allakos
Historical stock prices
Current Share PriceUS$1.19
52 Week HighUS$3.36
52 Week LowUS$0.54
Beta0.91
1 Month Change15.53%
3 Month Change90.71%
1 Year Change-56.41%
3 Year Change-87.87%
5 Year Change-98.71%
Change since IPO-96.19%

Recent News & Updates

Allakos Runs Up Into A Near-Term Catalyst

Nov 07

We Think Allakos (NASDAQ:ALLK) Needs To Drive Business Growth Carefully

Aug 27
We Think Allakos (NASDAQ:ALLK) Needs To Drive Business Growth Carefully

Recent updates

Allakos Runs Up Into A Near-Term Catalyst

Nov 07

We Think Allakos (NASDAQ:ALLK) Needs To Drive Business Growth Carefully

Aug 27
We Think Allakos (NASDAQ:ALLK) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate

May 05
We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate

We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate

Dec 01
We're Keeping An Eye On Allakos' (NASDAQ:ALLK) Cash Burn Rate

Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth

Aug 03
Companies Like Allakos (NASDAQ:ALLK) Are In A Position To Invest In Growth

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Apr 20
Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 04
Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value

Allakos: Potential For Comeback With Lirentelimab With 2 Indications

Oct 18

Allakos prices ~$150M underwritten offering

Sep 19

Allakos falls as lead asset offers mixed results in late-stage trial

Sep 09

Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Aug 06
Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash Wisely

Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?

Apr 22
Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?

Allakos: Sad End To A Promising Asset

Dec 23

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

Dec 01
We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth

Aug 16
We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business Growth

Allakos: Upcoming Phase 3 Data Makes The Stock Interesting

Aug 06

Allakos provides lirentelimab clinical trial enrollment updates, names new CMO

Jun 07

We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

May 02
We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash Wisely

Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?

Mar 10
Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?

Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling

Jan 28
Allakos Inc. (NASDAQ:ALLK) Insiders Have Been Selling

We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow

Dec 07
We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To Grow

Allakos EPS misses by $0.02

Nov 09

Shareholder Returns

ALLKUS BiotechsUS Market
7D-7.8%-1.7%-1.1%
1Y-56.4%-5.0%22.4%

Return vs Industry: ALLK underperformed the US Biotechs industry which returned -3.4% over the past year.

Return vs Market: ALLK underperformed the US Market which returned 23.7% over the past year.

Price Volatility

Is ALLK's price volatile compared to industry and market?
ALLK volatility
ALLK Average Weekly Movement23.0%
Biotechs Industry Average Movement10.8%
Market Average Movement6.3%
10% most volatile stocks in US Market17.6%
10% least volatile stocks in US Market3.1%

Stable Share Price: ALLK's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ALLK's weekly volatility has increased from 18% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012131Robert Alexanderwww.allakos.com

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Allakos Inc. Fundamentals Summary

How do Allakos's earnings and revenue compare to its market cap?
ALLK fundamental statistics
Market capUS$116.15m
Earnings (TTM)-US$178.74m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.6x

P/E Ratio

Is ALLK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALLK income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$178.75m
Earnings-US$178.74m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.00
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ALLK perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 07:53
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Allakos Inc. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Jason ZemanskyBofA Global Research
Jennifer KimCantor Fitzgerald & Co.